No pranks here.

Skip the fake news this April 1st. Use a "Vote to Enter" contest to let your customers tell you what they REALLY want in Q2.

Validate product demand + boost engagement.
buff.ly/bsARX9c

#AprilFools #ProductMarketing

Shopify Automation Is Now Available in Postoria Discover Shopify automation in Postoria and automatically turn new products into social posts.

Postoria now supports Shopify automation, making it easier to turn new Shopify products into social posts automatically.

Read more: https://postoria.io/blog/shopify-automation

#Shopify #SocialMediaAutomation #EcommerceMarketing #ProductMarketing #SocialMediaTools

AI isn’t about replacing marketers, it’s about empowering them.

See Airship’s approach to responsible AI innovation that simplifies creation, accelerates decisions and protects what matters most: trust.

➡️ https://bit.ly/3YfQc8v

#AI #ProductMarketing #GrowthMarketing #ResponsibleAI #CX

Hot take: AI killed the art of blog writing.

Not because AI writes bad content (okay maybe alittle), but because it writes enough content that nobody needs to stop and read yours.

We're drowning in posts that are technically correct but completely […]

[Original post on mastodon.social]

Careers - interos.ai interos.ai is a place where employees have the opportunity to achieve their career goals and advance technically and professionally.

Senior Director of product marketing role at InterOS

www.interos.ai/careers/

#GetFediHired #Jobs #ProductMarketing

Separating Meaning from Voice in Product Marketing How AI enables a clearer division of responsibilities, and where that division breaks down

Most problems people blame on “AI writing” aren’t about models or prompts.
They’re about who owns meaning.
I wrote this up as a longer piece here →
#ProductMarketing #AIinMarketing #ContentStrategy
www.retiredpdx.com//p/separatin...

𝗗𝗼𝗻’𝘁 𝗷𝘂𝘀𝘁 𝗽𝗼𝘀𝘁 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗽𝗵𝗼𝘁𝗼𝘀.𝗣𝗼𝘀𝘁 𝘃𝗶𝘀𝘂𝗮𝗹𝘀 𝘁𝗵𝗮𝘁 𝘀𝗲𝗹𝗹.

We design premium product showcase images from your raw product photo.

Your customers will notice the difference.

📩 Message us on WhatsApp to get started: wa.me/+8801560006032

🌐 Visit our website: www.teczoo.agency

#ProductMarketing #TecZoo

Take a look at this custom trade show giveaway building kit we developed for DIRTT, designed to reflect the flexibility of their modular prefabricated panel systems.

#TradeshowMarketing #BrandExperience
#Buildingkits #ModularDesign #ProductMarketing

Stop shouting into the market. Start controlling the board.
With Dappsfirm’s #ProductMarketing Services, we turn strategy into visibility and visibility into demand—so your product wins minds, clicks, and revenue.

Visit - www.dappsfirm.com/product-mark...

#dappsfirm #digitalmarketing #marketing

Product Marketing Benefits?

#productmarketing #aivideo #ProductMarketFit

Grail's cancer test misses primary study goal in UK study Grail on Thursday reported that its cancer test showed promise but failed to meet its primary goal in a large UK study, tanking the company's stock in after-hours trading. Grail {$GRAL} was trading around ...

Signal or noise? > Grail's cancer test misses primary study goal in UK
study >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #pharmaceutical #productmarketing

A psychedelic medicine performs well against depression Regulators are now mulling the results of the late-stage trial

Signal or noise? > A psychedelic medicine performs well against
depression >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #biotech #productmarketing

AbbVie, PhRMA can proceed with 340B case in Hawaii A federal judge is allowing AbbVie and PhRMA to proceed with most of their claims against a Hawaii state law that regulates how 340B-discounted drugs are distributed. Thursday's decision dealt an ...

Signal or noise? > AbbVie, PhRMA can proceed with 340B case in Hawaii >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #productmarketing #biotech

AI isn’t about replacing marketers, it’s about empowering them.

See Airship’s approach to responsible AI innovation that simplifies creation, accelerates decisions and protects what matters most: trust.

➡️ https://bit.ly/3YfQc8v

#AI #ProductMarketing #GrowthMarketing #ResponsibleAI #CX

Altesa raises $75M for oral respiratory med Altesa BioSciences has closed a $75 million Series B, enough to finance a Phase 2b study of its oral respiratory drug meant to prevent serious COPD exacerbations. The raise announced Thursday adds fresh capital for ...

Signal or noise? > Altesa raises $75M for oral respiratory med >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech

Brain-like computers could be built out of perovskites The long-hyped materials may have found their niche

Signal or noise? > Brain-like computers could be built out of
perovskites >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #healthcare #pharmaceutical

Medicare Part D Pharmacy Networks in 2026: Supermarkets Dominate as Drugstores Stall and Independents Walk Away The Centers for Medicare & Medicaid Services (CMS) has just released its initial 2026 data on enrollment in Medicare Part D prescription drug plans (PDPs). DCI’s exclusive analysis shows that 83% of seniors remain enrolled in PDPs with preferred pharmacy networks—essentially unchanged from 82% in 2025, but sharply lower than the 99% peak in 2023. Meanwhile, the number of major Part D plans offering preferred networks has fallen to a record-low eight. The new enrollment data reveal a clear shift in competitive positioning: Albertsons and Publix are now preferred in every major plan. Walgreens is holding strong. Walmart—the company that invented the Part D preferred network model—has slipped to the middle of the preferred pack. Meanwhile, smaller pharmacies have fully abandoned PDPs’ preferred networks in 2026. At the same time, the IRA’s expansion of the Low-Income Subsidy (LIS) means a growing share of beneficiaries have little financial incentive to use a preferred pharmacy at all. Add in the PBM reforms in the Consolidated Appropriations Act of 2026, and the preferred network model will gradually lose relevance. Read more » © 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.        

Signal or noise? > Medicare Part D Pharmacy Networks in 2026: Supermarkets
Dominate as Drugstores Stall and Independents Walk Away >> Comment below! #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical

Novartis signs macrocyclic deal with Unnatural Products for $100M upfront Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...

Signal or noise? > Novartis signs macrocyclic deal with Unnatural Products for
$100M upfront >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare

How has private equity hospital ownership impact the quality of labor & delivery care? The number of hospitals owned by private equity (PE) firms has increased in recent years. One key question is how increased PE ownership has impact quality of care. To answer the question, a Jiao 2025 Health Services Research paper used claims Medicaid claims data–specifically data from the Transformed Medicaid Statistical Information System (T-MSIS) and Medicaid…

Signal or noise? > How has private equity hospital ownership impact the quality
of labor & delivery care? >> Comment below! #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #productmarketing #pharmaceutical

Leo Pharma says it's turned a profit for the first time in seven years For the first time since 2018, Leo Pharma said it turned a profit last year thanks to new brands on the market and rising sales in the US. The dermatology-focused company collected 2.49 billion Danish ...

Signal or noise? > Leo Pharma says it's turned a profit for the first time in
seven years >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #pharma #productmarketing

Unlocking health data I was in Washington, DC, last week for the two-day ASTP Annual Meeting that brought together HHS officials, health data company execs and others involved in digital health. For me, it was a deep dive ...

Signal or noise? > Unlocking health data >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #pharmaceutical #biotech

Ocular Therapeutix’s Axpaxli could become first choice in wet AMD after showing superiority over Eylea Ocular Therapeutix’ investigational drug could become the preferred therapy for wet age-related macular degeneration after data released Tuesday showed statistical superiority to Regeneron and Bayer’s current bestseller Eylea. However, the data from the trial appear ...

Signal or noise? > Ocular Therapeutix’s Axpaxli could become first choice in
wet AMD after showing superiority over Eylea >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #healthcare #pharma #biotech

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more Welcome back to Endpoints Weekly! A programming note: We won’t be sending our usual newsletters on Monday, Feb. 16. Our team will be off for Presidents’ Day. Our reporters closely followed several big updates this ...

Signal or noise? > Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical
trials are so costly; and more >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #productmarketing #healthcare

The Key to a Better Patient Experience: Improved GTN Today’s guest post comes from Gerard Rivera, CEO and Co-Founder of RIS Rx. Gerard reframes patient affordability as a clinical issue rather than a purely financial one. He argues that real-time precision, earlier intervention, and coordinated escalation can reduce gross-to-net failures and improve the patient experience. To learn more about RIS Rx’s approach, request a RIS Rx savings snapshot. Read on for Gerard’s insights. Read more » © 2006-2026 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.        

Signal or noise? > The Key to a Better Patient Experience: Improved GTN >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #productmarketing

Can the shingles vaccine slow ageing? The evidence is surprisingly strong

Signal or noise? > Can the shingles vaccine slow ageing? >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech

Friday Links Expert opinions: Will MFN reduce US drug prices? Robots in maternity care. What drives company decisions on new medicine launches and UK investment? Incorporating dynamic pricing into HEOR models (dynamicpv) Tale of 2 value sets. How to handle the lows? Honesty. Integrity in journalism: Giannis edition.

Signal or noise? > Friday Links >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #pharma #healthcare

Gilead gets cancer drug from China-based Genhouse for $80M upfront Gilead is buying the global rights to an oral cancer drug from Genhouse Bio, a China-based biotech that filed for an IPO on the Hong Kong Stock Exchange last month. ...

Signal or noise? > Gilead gets cancer drug from China-based Genhouse for $80M
upfront >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #biotech #healthcare #pharmaceutical #pharma

Lilly appeals retatrutide classification ruling in case that could impact compounders Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...

Signal or noise? > Lilly appeals retatrutide classification ruling in case that
could impact compounders >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical

Epigenetic editing startup Moonwalk shifts focus to siRNA for obesity Two years ago, CRISPR gene editing pioneer Feng Zhang and former Illumina chief technology officer Alex Aravanis launched a startup to develop medicines that would change how genes are turned on and ...

Signal or noise? > Epigenetic editing startup Moonwalk shifts focus to siRNA
for obesity >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #productmarketing #pharma

Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class Lundbeck said its next-generation migraine prevention drug cleared the bar in a Phase 2b study, setting the company up for late-stage trials that could start this year. The Danish drugmaker said the IV-delivered medicine, bocunebart ...

Signal or noise? > Lundbeck migraine prevention drug succeeds in Phase 2,
advancing new therapy class >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #biotech #pharma #healthcare